不同剂量阿托伐他汀联合胰激肽原酶肠溶片治疗糖尿病动脉粥样硬化患者的疗效

Effect of different doses of atorvastatin combined with pancreatic kininogenase enteric-coated tablets in the treatment of diabetic atherosclerosis

目的:研究不同剂量阿托伐他汀与胰激肽原酶肠溶片结合治疗糖尿病动脉粥样硬化的疗效及其对炎症因子的影响。方法:选取146例糖尿病动脉粥样硬化患者作为研究对象,按照治疗方式不同将患者分为对照组和观察组,每组各73例。对照组接受低剂量(20 mg/d)阿托伐他汀与胰激肽原酶肠溶片治疗;观察组接受高剂量(40 mg/d)阿托伐他汀与胰激肽原酶肠溶片治疗。对比两组在治疗前后的血糖、血脂、治疗效果、炎症指标、血管内皮功能、动脉粥样硬化状态及不良反应发生情况。结果:治疗后,观察组的甘油三酯(TG)、总胆固醇(TC)、白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)、C反应蛋白(CRP)、内皮素1(ET-1)水平、斑块面积及厚度均低于对照组,高密度脂蛋白胆固醇(HDL-C)、一氧化氮(NO)和6酮前列环素1α(6-Keto-PGF1α)水平高于对照组(P<0.05)。观察组治疗有效率优于对照组(P<0.05)。两组不良反应总发生率无统计学差异(P>0.05)。结论:对于糖尿病导致的动脉粥样硬化,高剂量阿托伐他汀配合胰激肽原酶肠溶片能更有效地减轻症状,有助于降低血脂和炎症反应,同时有助于减小斑块和改善血管内皮功能,具有显著的临床疗效和良好的安全性。

Objective:To investigate the clinical effect of different doses of atorvastatin combined with pancreatic kininogenase enteric-coated tablets in the treatment of diabetic arteries sclerosis patients and the effect on inflammatory factor.Methods:146 cases of patients with diabetes arteriosclerosis were divided into control group and observation group according to different treatment methods,with 73 cases in each group.The control group was treated with conventional 20 mg/d atorvastatin combined with pancreatic kininogenase enteric-coated tablets,and the observation group was treated with high-dose 40 mg/d atorvastatin combined with pancreatic kininogenase enteric-coated tablets.Blood glucose,blood lipids,clinical efficacy,inflammatory factors,vascular endothelial function,atherosclerotic status and the occurrence of adverse effects before and after treatment were recorded and compared between the two groups.Results:The triglycerides(TG),total cholesterol(TC),interleukin-6(IL-6),tumor necrosis factorα(TNF-α),C-reactive protein(CRP),endothelin-1(ET-1),plaque area,and plaque thickness levels in the observation group were lower than those in the control group after intervention,while the high-density lipoprotein cholesterol(HDL-C),nitric oxide(NO),and 6-Keto-Prostaglandin F1alpha(6-Keto-PGF1α)levels in the observation group were higher than those in the control group(P<0.05).The treatment effectiveness rate of the observation group was higher than that of the control group(P<0.05),while the incidence of adverse reactions was no statistically significant difference compared with the control group(P>0.05).Conclusion:For patients with diabetes-induced atherosclerosis,the use of high-dose atorvastatin combined with pancreatic kininogenase enteric-coated tablets is more conducive to the relief of the patient s condition,which can be conducive to lowering the patient s blood lipids and the degree of inflammatory response,as well as reducing the plaque and improving the function of the vascular endothelium,with significant clinical efficacy and better safety.